Method for differentiating azole-based antifungal drug-resistant trichophyton indotineae using CYP51b tandem repeat
The method uses specific primer sets for nucleic acid amplification to identify tandem repeats of the CYP51B gene, addressing the challenge of differentiating resistant and susceptible strains of Trichophyton indotineae, achieving efficient and cost-effective azole antifungal drug resistance prediction.
Patent Information
- Application Number
- PCT/JP2024/017258
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-14
AI Technical Summary
Current methods are inadequate for quickly and cost-effectively differentiating between susceptible and resistant strains of Trichophyton indotineae to azole antifungal drugs, as they require expensive whole genome sequencing to determine the copy number of the CYP51B gene.
A method involving specific primer sets for nucleic acid amplification reactions to identify tandem repeats of the CYP51B gene, allowing for the differentiation of azole antifungal drug-resistant strains by analyzing PCR products, which is faster and more economical than traditional sequencing methods.
Enables rapid and inexpensive differentiation between susceptible and resistant strains of Trichophyton indotineae to azole antifungal drugs, predicting resistance based on the presence of tandem repeat structures without the need for expensive next-generation sequencing.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure JPOXMLDOC01-APPB-T000003
Abstract
Description
Method for identifying azole antifungal drug-resistant Trichophyton indotineae using tandem repeats of CYP51B
[0001] The present invention relates to a method for identifying azole antifungal drug-resistant Trichophyton indotineae, utilizing the tandem repeats of CYP51B.
[0002] In 2018, numerous outbreaks of tinea corporis resistant (low susceptibility) to terbinafine (TBF), an allylamine antifungal drug, were reported in India, and the causative agent was identified as Trichophyton interdigitale. In 2020, Kano et al. proposed that the TBF-resistant T. interdigitale be a new species, Trichophyton indotineae (Non-Patent Document 1).
[0003] In 2022, the present inventors reported that resistance to azole antifungal drugs (itraconazole, voriconazole) in T. indotineae is due to overexpression of the CYP51B gene (TinCYP51B) due to an increase in the copy number of the gene (Non-Patent Document 2).
[0004] Kano, R. et al., Trichophyton indotineae sp. nov.: A New Highly Terbinafine-Resistant Anthropophilic Dermatophyte Species. Mycopathologia 185, 947-958 (2020). Yamada, T. et al., Gene Amplification of CYP51B: a New Mechanism of Resistance to Azole Compounds in Trichophyton indotineae. Antimicrobial Agents and Chemotherapy June 2022 Volume 66 Issue 6.
[0005] In Non-Patent Document 2, the duplicate copy number of the CYP51B gene was determined by determining the whole genome sequence of T. indotineae using a next-generation sequencer, and there has been a demand for a cheaper and more rapid method for distinguishing between susceptible strains and resistant strains.
[0006] The above-mentioned problems can be solved by the present invention as follows: [1] A step of preparing a genomic DNA sample from the tinea fungus Trichophyton indotineae (T. indotineae) to be differentiated; (1) a combination of a first forward primer comprising a nucleotide sequence complementary to the antisense strand of the 3'-region of the CYP51B gene of the T. indotineae, and a first reverse primer comprising a nucleotide sequence complementary to the sense strand of the 5'-region of the CYP51B gene, and / or (2) a combination of a second forward primer comprising a nucleotide sequence complementary to the 5'-untranslated region of the sense strand of the FYV4 gene of the T. indotineae, and a first reverse primer comprising a nucleotide sequence complementary to the antisense strand of the 5'-region of the CYP51B gene of the T. indotineae. [2] A method for distinguishing between azole antifungal drug-resistant strains of T. indotineae, comprising: performing a nucleic acid amplification reaction using the genomic DNA sample as a template with a combination of a third forward primer comprising a nucleotide sequence complementary to the antisense strand of the 5'-end region of the CYP51B gene and a second reverse primer comprising a nucleotide sequence complementary to the sense strand of the 3'-end region of the CYP51B gene, or the method of [1] further comprising the steps of: performing a nucleic acid amplification reaction using the genomic DNA sample as a template with a combination of a third forward primer comprising a nucleotide sequence complementary to the antisense strand of the 5'-region of the VeA gene of S. indotineae and a third reverse primer comprising a nucleotide sequence complementary to the sense strand of the 3'-region of the VeA gene; and using the resulting nucleic acid amplification product as a positive control.
[0007] According to the present invention, it is possible to more inexpensively and quickly distinguish between strains of T. indotineae that are sensitive to azole antifungal drugs and those that are resistant to them.
[0008]
[0023] Figure 1 is an explanatory diagram schematically showing the location of the CYP51B gene (TinCYP51B) on the genome in an azole antifungal drug-resistant strain (Type 1) and a drug-susceptible strain of T. indotineae, and the annealing positions and their base sequences of the two primer sets (F1 and R1, F2 and R2) used in Example 1.
[0024] Figure 1 is an explanatory diagram schematically showing the location of the CYP51B gene (TinCYP51B) and its neighboring genes (TinCHKB, TinFYV4) on the genome in an azole antifungal drug-resistant strain (Type 1, Type 2) and a drug-susceptible strain of T. indotineae.
[0025] Figure 2 is an explanatory diagram schematically showing the annealing positions and their base sequences of the three primer sets (combination of P1 and P2, combination of P3 and P4, combination of P5 and P6) used in Example 2. Electrophoretic images showing the results of agarose gel electrophoresis of PCR amplification products (DNA fragments) carried out under the PCR reaction conditions shown in Fig. 4 using each primer set shown in Fig. 1. Electrophoretic images showing the results of agarose gel electrophoresis of amplification products (DNA fragments) obtained by carrying out multiplex PCR using a PCR reaction solution containing the six types of primers shown in Fig. 3.
[0009] (Principle of the Differential Reaction of the Present Invention) As shown in Figure 1 and Table 1, in azole antifungal drug-susceptible strains of T. indotineae (hereinafter sometimes simply referred to as "susceptible strains"), the copy number of the TinCYP51B gene is 1, whereas in azole antifungal drug-resistant strains (hereinafter sometimes simply referred to as "resistant strains"), the copy number of the TinCYP51B gene is multiple (e.g., 3 to 7), and in the resistant strains, duplicated TinCYP51B genes are repeated in a row in the same direction on the genome (tandem repeat structure). In the resistant strains, the copy number of the TinCYP51B gene is increased, resulting in overexpression of the gene, which results in resistance to azole antifungals.
[0010] The resistant strains shown in Figure 1 and Table 1 are Type 1 resistant strains in which only the TinCYP51B gene has a tandem repeat structure, as shown in Figures 2 and 3. The present inventors have now newly discovered that among the resistant strains, there exists a Type 2 resistant strain as shown in Figures 2 and 3. As shown in Figures 2 and 3, Type 2 resistant strains have, in addition to the TinCYP51B gene, a TinCHKB gene located near the 5' upstream of the TinCYP51B gene and a TinFYV4 gene located near the 5' downstream of the TinCYP51B gene, which form a block, and the block unit of the TinCHKB gene, TinCYP51B gene, and TinFYV4 gene forms a tandem repeat structure, thereby conferring resistance to azole antifungal drugs.
[0011] In the differentiation method of the present invention, a primer set essential for differentiating Type 1 strains is used, which is a combination of a first forward primer (e.g., forward primer F1 in Figure 1 and forward primer P1 in Figure 3) containing a base sequence complementary to the antisense strand of the 3' region of the TinCYP51B gene and a first reverse primer (e.g., reverse primer R1 in Figure 1 and reverse primer P2 in Figure 3) containing a base sequence complementary to the sense strand of the 5' region of the TinCYP51B gene (hereinafter, sometimes referred to as the first essential primer set).
[0012] Furthermore, a primer set essential for distinguishing type 2 strains is a combination of a second forward primer (e.g., forward primer P3 in Figure 3) containing a base sequence complementary to the 5' untranslated region of the sense strand of the TinFYV4 gene and a second reverse primer (e.g., reverse primer P4 in Figure 3) containing a base sequence complementary to the 5' untranslated region of the sense strand of the TinCHKB gene (hereinafter, this may be referred to as the second essential primer set).
[0013] Furthermore, if desired, in a preferred embodiment of the differentiation method of the present invention, as a positive control, a combination of a third forward primer (e.g., forward primer F2 in FIG. 1) containing a nucleotide sequence complementary to the antisense strand of the 5' region of the TinCYP51B gene and a third reverse primer (e.g., reverse primer R2 in FIG. 1) containing a nucleotide sequence complementary to the sense strand of the 3' region of the TinCYP51B gene, or a fourth forward primer (e.g., forward primer P5 in FIG. 3) containing a nucleotide sequence complementary to the antisense strand of the 5' region of the VeA gene (SEQ ID NO: 19) commonly present in the genomic DNA of T. indotineae and a fourth reverse primer (e.g., reverse primer P6 in FIG. 3) containing a nucleotide sequence complementary to the sense strand of the 3' region of the VeA gene (hereinafter, sometimes referred to as a positive control primer set) can also be used.
[0014] When a nucleic acid amplification reaction is performed using a genomic DNA sample of T. indotineae as a template and the first essential primer set, the region between the first forward primer and the first reverse primer is amplified in the resistant strain (see the combination of F1 and R1 in the upper schematic diagram of Figure 1 or the combination of P1 and P2 in Figure 3), resulting in a nucleic acid amplification product of the expected size (see lanes 3 to 5 in the agarose gel electrophoresis image on the left side of Figure 4, or lanes 2 and 4 in the agarose gel electrophoresis image of Figure 5). On the other hand, when a nucleic acid amplification reaction is performed using the same genomic DNA sample as a template and the same first essential primer set in the susceptible strain, the extension direction of each primer is reversed (see the combination of F1 and R1 in the lower schematic diagram of Figure 1, or the combination of P1 and P2 in Figure 3), and therefore no nucleic acid amplification product is generated (see lanes 1 and 2 in the agarose gel electrophoresis image on the left side of Figure 4, or lanes 1 and 3 in Figure 5).
[0015] Therefore, by using the first essential primer set, it is possible to determine whether or not a strain has Type 1, i.e., a tandem repeat structure of the TinCYP51B gene, or whether or not the copy number of TinCYP51B is 1. That is, if a strain has a tandem repeat structure, it can be distinguished as a Type 1 resistant strain, and if the copy number is 1, it can be distinguished as a susceptible strain.
[0016] On the other hand, when a nucleic acid amplification reaction is performed using a genomic DNA sample of T. indotineae as a template and the second essential primer set, the region sandwiched between the second forward primer and the second reverse primer is amplified in the resistant strain (see the combination of P3 and P4 in Figure 3 ), resulting in a nucleic acid amplification product of the expected size (see lanes 5 to 7 in the agarose gel electrophoresis image of Figure 5 ). On the other hand, when a nucleic acid amplification reaction is performed using the same genomic DNA sample as a template and the same second essential primer set in the susceptible strain, the extension direction of each primer is reversed (see the combination of P3 and P4 in Figure 3 ), so no nucleic acid amplification product is generated (see lanes 1 and 3 in the agarose gel electrophoresis image of Figure 5 ).
[0017] Therefore, by using the second essential primer set, it is possible to determine whether or not a strain has a type 2, i.e., a block-unit tandem repeat structure consisting of the TinCHKB gene, the TinCYP51B gene, and the TinFYV4 gene, or whether or not the copy number of the block unit is 1. That is, if a strain has the block-unit tandem repeat structure, it can be distinguished as a type 2 resistant strain, and if the copy number is 1, it can be distinguished as a susceptible strain.
[0018] In a preferred embodiment of the differentiation method of the present invention, when a positive control primer set is used, the region sandwiched between the third forward primer and the third reverse primer, or the fourth forward primer and the fourth reverse primer, is amplified in both resistant and susceptible strains (see the combination of F2 and R2 in the upper and lower schematic diagrams of Figure 1, or P5 and P6 in the lower schematic diagram of Figure 3), and a nucleic acid amplification product of the expected size is obtained (see lanes 1 to 5 in the agarose gel electrophoresis image on the right of Figure 4, or lanes 1 to 7 in the agarose gel electrophoresis image of Figure 5).Therefore, this primer set can be used as a positive control, i.e., to confirm whether the nucleic acid amplification reaction is proceeding normally, whether at least one copy of the TinCYP51B gene is contained in the genome, etc.
[0019] (Primer set used in the differentiation method of the present invention) The first essential primer set used in the present invention is a combination of a first forward primer (e.g., forward primer F1 in FIG. 1 or forward primer P1 in FIG. 3) containing a nucleotide sequence complementary to the antisense strand of the 3' region of the TinCYP51B gene, and a first reverse primer (e.g., reverse primer R1 in FIG. 1 or reverse primer P2 in FIG. 3) containing a nucleotide sequence complementary to the sense strand of the 5' region of the TinCYP51B gene, and is not particularly limited as long as the combination can amplify a region including the region between adjacent TinCYP51B genes when a tandem repeat structure of TinCYP51B genes is formed on the genome.
[0020] The nucleotide sequence of SEQ ID NO: 7 (7,700 bases in total) is the nucleotide sequence of the TinCYP51B gene (1 copy) and its surrounding region in the sensitive strain TIMM20114. The TinCYP51B gene (1,788 bases) corresponds to 3725-5512 in SEQ ID NO: 7. The nucleotide sequence of SEQ ID NO: 8 (21,261 bases in total) is the nucleotide sequence of the TinCYP51B gene (7 copies) and its surrounding region in the type 1 resistant strain TIMM20118. The nucleotide sequence of SEQ ID NO: 9 (26,683 bases in total) is the nucleotide sequence of the TinCYP51B gene (4 copies) and its surrounding region in the type 2 resistant strain TIMM20122.
[0021] The TinCYP51B gene has homologous sequences, AACCGAAAAGCAGC (3081-3094 of SEQ ID NO:7) and AAGCGAAAGCAGC (5486-5498 of SEQ ID NO:7), upstream of the start codon ATG (3725-3727 of SEQ ID NO:7) and upstream of the stop codon (5510-5512 of SEQ ID NO:7), respectively, and these homologous sequences are used to form a tandem repeat structure of TinCYP51B. Because the homologous sequence on the 3' side (5486-5498 of SEQ ID NO:7) is located upstream of the stop codon, when homologous recombination occurs, a small deletion occurs at the 3' end of the TinCYP51B gene.
[0022] The first essential primer set used in the present invention can be designed to target the region sandwiched between these homologous sequences, i.e., the region from 3095 to 5498 of SEQ ID NO: 7. The length of the primers is generally in the range of 10 to 40 bases, preferably 15 to 30 bases, and particularly preferably 16 to 25 bases. The distance between the primers, i.e., the amplified region, is not particularly limited as long as it is in the range of 100 to 5000 bases, but is preferably 100 to 2000 bases. The first essential primer sets F1 and R1 used in Example 1 correspond to 5113 to 5137 of SEQ ID NO: 7 and 3831 to 3855 of SEQ ID NO: 7, respectively. Furthermore, the first essential primer sets F1 and R1 correspond to, for example, 3923 to 3947 of SEQ ID NO: 8 and 5045 to 5069 of SEQ ID NO: 8, respectively. The first essential primer set P1 and P2 used in Example 2 correspond to 5103-5137 of SEQ ID NO: 7 and 3831-3865 of SEQ ID NO: 7, respectively. Furthermore, the first essential primer set P1 and P2 correspond to, for example, 3913-3947 of SEQ ID NO: 8 and 5045-5079 of SEQ ID NO: 8, respectively.
[0023] The first forward primer in the first essential primer set can be designed to target preferably the region of 4691-4890, more preferably the region of 5091-5290 in SEQ ID NO: 7. The first reverse primer in the first essential primer set can be designed to target preferably the region of 3990-4190, more preferably the region of 3690-3890 in SEQ ID NO: 7.
[0024] The second essential primer set P3 and P4 used in Example 2 bind to, for example, 3878-3912, 11251-11285, 18624-18658, and 25994-26028 (P3) of SEQ ID NO: 9, and 4635-4669, 12008-12042, and 19381-19415 (P4) of SEQ ID NO: 9. The TinFYV4 gene (783 bases) corresponds to 5941-6723 of SEQ ID NO: 7, and is contained at four positions in SEQ ID NO: 9 (3480-2698, 10853-10071, 118226-17444, and 25596-24817). The TinCHKB gene (2320 bases) corresponds to 605-2924 of SEQ ID NO: 7, and is contained in three positions (4736-7054, 12109-14427, 19482-21801) of SEQ ID NO: 9.
[0025] The positive control primer set that can be used in a preferred embodiment of the differentiation method of the present invention is a combination of a third forward primer (e.g., forward primer F2 in Figure 1) containing a base sequence complementary to the antisense strand of the 5' region of the TinCYP51B gene and a third reverse primer (e.g., reverse primer R2 in Figure 1) containing a base sequence complementary to the sense strand of the 3' region of the TinCYP51B gene, and is not particularly limited as long as the combination can amplify a partial region of the TinCYP51B gene.
[0026] The positive control primer set can also be designed to target the region 3095-5498 of SEQ ID NO: 7, and the same explanation as for the essential primer set can be applied to the length of the primers and the distance between the primers. The positive control primer sets F2 and R2 used in Example 1 correspond to regions 3719-3743 of SEQ ID NO: 7 and 4447-4471 of SEQ ID NO: 7, respectively.
[0027] The third forward primer in the positive control primer set can be designed to target preferably the region 3290-3490, more preferably the region 3590-3790 in SEQ ID NO: 7. The third reverse primer in the positive control primer set can be designed to target preferably the region 4690-4890, more preferably the region 4390-4590 in SEQ ID NO: 7.
[0028] A positive control primer set that can be used in another preferred embodiment of the differentiation method of the present invention is a combination of a fourth forward primer (e.g., forward primer P5 in FIG. 3) containing a nucleotide sequence complementary to the antisense strand of the 5' region of the TinVeA gene (SEQ ID NO: 19; 3670 bases) and a fourth reverse primer (e.g., reverse primer P6 in FIG. 3) containing a nucleotide sequence complementary to the sense strand of the 3' region of the TinVeA gene, and is not particularly limited as long as the combination can amplify a partial region of the TinVeA gene. The ORF position of the TinVeA gene in SEQ ID NO: 19 is from 238 to 1819.
[0029] (Distinguishing Method of the Present Invention) Each step in the distinguishing method of the present invention, for example, culturing T. indotineae, preparing a genomic DNA sample, nucleic acid amplification reaction, and confirmation of the nucleic acid amplification product, can be carried out according to a standard method.
[0030] The present invention will be specifically described below with reference to examples, but these examples are not intended to limit the scope of the present invention.
[0031] Example 1 Differentiation of Azole Antifungal Drug-Resistant Strains (Type 1) and Susceptible Strains in T. indotineae In this example, PCR was performed to amplify the CYP51B gene (TinCYP51B) and its surrounding regions using genomic DNA extracted from six strains of the tinea fungus Trichophyton indotineae (T. indotineae) that were susceptible or resistant to azole antifungals (itraconazole, voriconazole) and two pairs of PCR primers (a first combination of F1 and R1, and a third combination of F2 and R2), and the presence or absence of the resulting nucleic acid amplification product was examined to determine the relationship between susceptibility / resistance to azole antifungals.
[0032] As T. indotineae, the sensitive strains used were TIMM20114 and TIMM20115, and the resistant strains used were TIMM20116, TIMM20118, TIMM20119, and IFM66168 (strains beginning with TIMM were obtained from the culture collection of the Teikyo University Medical Mycology Research Center, and strains beginning with IFM were obtained from the Chiba University Medical Mycology Research Center). The genomic DNA of S. indotineae was obtained by collecting growing mycelia cultured on Sabouraud Dextrose Agar (BD Biosciences) for 3-4 days, freezing them in liquid nitrogen, and then pulverizing them using a Multi-Beads shocker (Yasuhi Kikai). The DNA was then extracted according to the method of Girardin and Latge [Girardin H, Latge JP. 1994. DNA extraction and quantification, p. 5-9. In Molecular biology of pathogenic fungi, 2 nd The samples were extracted using the method described in Maresca B, Kobayashi GS, (eds). Telos Press, New York, NY.
[0033] As PCR primers, a first combination was used, which consisted of forward primer F1 (SEQ ID NO: 1; 25 bases) and reverse primer R1 (SEQ ID NO: 2; 25 bases) as shown in FIG. 1 , and a third combination was used, which consisted of forward primer F2 (SEQ ID NO: 4; 25 bases) and reverse primer R2 (SEQ ID NO: 5; 25 bases) as shown in FIG. 1 . Specific base sequences are shown below. The base sequences of SEQ ID NOs: 3 and 6 are the sense strand sequences of the CYP51B gene of T. indotineae, which are the target sequences of R1 and R2, respectively. F1: 5'-CTCTTGTTTGGAACCCTCACCGATG-3' (SEQ ID NO: 1) R1: 5'-AGCTGCTGCAGGACGTTGATAACAA-3' (SEQ ID NO: 2) F2: 5'-ATCACCATGGGCCTCTTAGCCGACA-3' (SEQ ID NO: 4) R2: 5'-GAGGCGGTGTAGATGGTGATTTCAG-3' (SEQ ID NO: 5) Target sequence of R1: 5'-TTGTTATCAACGTCCTGCAGCAGCT-3' (SEQ ID NO: 3) Target sequence of R2: 5'-CTGAAATCACCATCTACACCGCCTC-3' (SEQ ID NO: 6) It is possible to use a forward primer F1 of the following sequence instead of F1 of SEQ ID NO: 1: F1: 5'-TCTTGTTTGGAACCCTCACCGATGG-3' (SEQ ID NO: 20)
[0034] When PCR is performed using the combination of F1 and R1, an amplified band of a predetermined base length is detected in azole antifungal drug-resistant strains because the TinCYP51B gene forms tandem repeats, as shown in Figure 1, but an amplified band is not detected in azole antifungal drug-susceptible strains because the copy number of the TinCYP51B gene is 1. On the other hand, when PCR is performed using the combination of F2 and R2 used as a positive control, an amplified band of a predetermined base length is detected in both azole antifungal drug-resistant and -susceptible strains, as shown in Figure 1.
[0035] PCR was carried out under the conditions shown in Figure 4. The resulting amplification products were subjected to electrophoresis using 0.8% (w / v) agarose gel.
[0036] The electrophoretic image of the PCR-amplified CYP51B gene product is shown in Figure 4. The susceptibility (MIC) of each T. indotineae strain to itraconazole (ITC) and voriconazole (VRC) was also measured. 80 The MIC values for the CYP51B gene, the susceptibility / resistance to azole antifungal drugs, the relative expression level of the CYP51B gene, and the number of duplicated copies of the CYP51B gene in the genome are summarized in Table 1 (the number of duplicated copies in the resistant strains was estimated based on the results of the analysis of the whole genome sequence). 80 "(A)" is the lowest concentration (unit: μg / mL) of antifungal agent present in the well that exhibits 80% growth inhibition compared to the absorbance value obtained without the antifungal agent. The relative expression level of the CYP51B gene is shown as a relative value (mean ± SD) to the TIMM20114 strain, based on the expression level obtained by real-time PCR (N = 3). Furthermore, the number of duplicated copies of the CYP51B gene in the genome was based on the whole genome sequence determined by next-generation sequencing.
[0037]
[0038] The azole antifungal drug-susceptible strains TIMM20114 and TIMM20115 had a CYP51B gene copy number of 1 as determined from the whole genome sequence, and an amplification product (DNA fragment) was detected in a PCR reaction using the positive control combination of F2 and R2, but no amplification product was detected in a PCR reaction using the combination of F1 and R1. On the other hand, the (estimated) duplicated copy numbers of the CYP51B gene in the azole antifungal drug-resistant strains TIMM20116, TIMM20118, TIMM20119, and IFM66168 were 5 copies, 7 copies, 5 copies, and 3 copies, respectively, and an amplification product was detected in a PCR reaction using either the combination of F1 and R1 or the combination of F2 and R2. Although the electrophoresis image of the TIMM20116 strain is not included in Figure 4, it has been separately confirmed that an amplification product with the same molecular weight as that of the TIMM20118 strain, the TIMM20119 strain, and the IFM66168 strain is detected.
[0039] The relative expression level of the CYP51B gene increases depending on the number of duplicated copies of the CYP51B gene, and it is believed that this increase in relative expression level leads to resistance to azole antifungal drugs. According to the present invention, it is possible to predict whether or not the CYP51B gene forms tandem repeats based on the presence or absence of bands in the PCR amplification product without determining the whole genome sequence using an expensive next-generation sequencer, and it is possible to determine whether or not there is resistance to azole antifungal drugs by inexpensive, routine PCR and the electrophoretic image of the amplification product, i.e., it is possible to distinguish between sensitive and resistant strains.
[0040] Example 2: Differentiation of Type 1 and Type 2 Strains of T. indotineae Resistant to Azole Antifungal Drugs In this example, the azole antifungal drug-resistant strains shown in Table 2 (Ebert A, Monod M, Salamin K, Burmester A, Uhrlass S, Wiegand C, Hipler UC, Kruger C, Koch D, Wittig F, Verma SB, Singal A, Gupta S, Vasani R, Saraswat A, Madhu R, Panda S, Das A, Kura MM, Kumar A, Poojary S, Schirm S, Graser Y, Paasch U, Nenoff P. 2020. Alarming India-wide phenomenon of antifungal resistance in dermatophytes: a multicenter study. Mycoses Genomic DNA samples extracted from seven strains (TIMM20114, TIMM20115, TIMM20118, TIMM20119, TIMM20121, TIMM20122, and TIMM20123) of the 1999 MRSA (63:717-728) were used to differentiate between type 1 and type 2 strains.
[0041]
[0042]
[0043] The PCR primers used were a combination of forward primer P1 and reverse primer P2 as the first combination used to distinguish Type 1 strains, a combination of forward primer P3 and reverse primer P4 as the second combination used to distinguish Type 2 strains, and a combination of forward primer P5 and reverse primer P6 as the positive control. Specific base sequences are shown below. P1: 5'-TTCCCTGACCCTCTTGTTTGGAACCCTCACCGATG-3' (SEQ ID NO: 10) P2: 5'-CTTGAACAGGAGCTGCTGCAGGACGTTGATAACAA-3' (SEQ ID NO: 11) P3: 5'-GAGCTGCTCAGAGCAGTGTCTCACTCTTGTGCCAC-3' (SEQ ID NO: 13) P4: 5'-GCAACTTCAACTCCAAGTCGATGGCAGGCAAGATC-3' (SEQ ID NO: 14) P5: 5'-GTCCTTATGCTCACGGCAGAGTG-3' (SEQ ID NO: 16) P6: 5'-CCTTCCATGCCCGAGTTGCTGGC-3' (SEQ ID NO: 17) Target sequence of P2: 5'-TTGTTATCAACGTCCTGCAGCAGCTCCTGTTCAAG-3' (SEQ ID NO: 12) Target sequence of P4: 5'-GATCTTGCCTGCCATCGACTTGGAGTTGAAGTTGC-3' (SEQ ID NO: 15) Target sequence of P6: 5'-GCCAGCAACTCGGGCATGGAAGG-3' (SEQ ID NO: 18)
[0044] A PCR reaction solution containing six primers (P1 to P6) was prepared, and multiplex PCR reactions were performed using genomic DNA extracted from seven strains of Trichophyton indotineae (T. indotineae) as templates under the temperature conditions shown in Figure 5. As shown in Figure 3, an amplified band of the expected base length was detected in each of the azole antifungal drug-resistant strains having type 1 block units and the azole antifungal drug-resistant strains having type 2 block units, but no amplified band was detected in the azole antifungal drug-susceptible strain because the TinCYP51B gene copy number was one. On the other hand, the combination of positive control primers P5 and P6 detected an amplified band of the same base length in both the azole antifungal drug-resistant and -susceptible strains, as shown in Figure 3.
[0045] The electrophoretic patterns of the PCR-amplified gene products are shown in Figure 5. Lanes 1 and 3 are negative control azole antifungal drug-susceptible strains (strains TIMM20114 and TIMM20115), lanes 2 and 4 are type 1 strains (strains TIMM20118 and TIMM20119), and lanes 5 to 7 are type 2 strains (strains TIMM20121, TIMM20122, and TIMM20123).
[0046] The present invention can be used to differentiate between strains of Trichophyton indotineae that are sensitive to azole antifungal drugs and those that are resistant to them.
Claims
1. A process for preparing a genomic DNA sample from the tinea fungus Trichophyton indotineae (T. indotineae) to be differentiated; (1) a combination of a first forward primer comprising a base sequence complementary to the antisense strand of the 3'-region of the CYP51B gene of T. indotineae and a first reverse primer comprising a base sequence complementary to the sense strand of the 5'-region of the CYP51B gene, and / or (2) a combination of a second forward primer comprising a base sequence complementary to the sense strand 5'-untranslated region of the FYV4 gene of T. indotineae and a second reverse primer comprising a base sequence complementary to the sense strand 5'-untranslated region of the CHKB gene of T. indotineae, and performing a nucleic acid amplification reaction using the genomic DNA sample as a template to analyze whether or not a nucleic acid amplification product of a predicted size is present; A method for identifying azole antifungal drug-resistant strains of S. indotinae.
2. The method according to claim 1, further comprising the steps of: performing a nucleic acid amplification reaction using the genomic DNA sample as a template with a combination of a third forward primer comprising a base sequence complementary to the antisense strand of the 5' region of the CYP51B gene and a third reverse primer comprising a base sequence complementary to the sense strand of the 3' region of the CYP51B gene, or a combination of a fourth forward primer comprising a base sequence complementary to the antisense strand of the 5' region of the VeA gene of T. indotineae and a fourth reverse primer comprising a base sequence complementary to the sense strand of the 3' region of the VeA gene, and using the obtained nucleic acid amplification product as a positive control;
Citation Information
Patent Citations
Methods and kits for detecting azole-resistant aspergillus fumigatus
JP2019013206A
Method for detecting a tandem repeat
WO2019234252A1
